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Background: Although non-adherence to antidepressant medications is a significant barrier to the successful treatment
of depression in clinical practice, few potentially modifiable predictors of poor adherence to antidepressant treatment
are known. The aim of this study was to examine the relationship of psychological reactance, health locus of control and
the sense of self-efficacy on adherence to treatment regimen among psychiatric outpatients with depression.
Methods: One hundred and forty-five consecutive psychiatric outpatients suffering from depressive disorders
were invited to participate in a cross-sectional study and 119 accepted. Patients completed a series of self-reported
questionnaires assessing psychological reactance, health locus of control, self-efficacy, and adherence to prescribed
medication in addition to socio-demographic and clinical variables. Logistic regression analyses were performed to
determine which factors better correlate to treatment adherence.
Results: Age was found to be the best correlate of adherence to prescribed treatment. As regards psychological
dimension studied, medication adherence was negatively associated with both cognitive and affective psychological
reactance; patients with higher psychological reactance were more likely to be noncompliant than patients showing a
low level of psychological reactance. Regarding health locus of control, only the external dimension of doctor-attributed
health locus of control was positively associated with medications adherence. No effect on adherence was observed for
the self-efficacy scale.
Conclusions: Psychological reactance is an important correlate of adherence to treatment in patients with depressive
disorders and this needs to be considered when giving clinical advice in order to avoid inducing reactance and thus
non-adherence to prescribed treatments. Mental health professionals need to learn about communication techniques
and counseling skills that enable them to deal with the psychological reactance of their patients.
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Depressive disorders are a major problem for public
health because of their very common presentation. They
are a major cause of disability and can cause death both
by suicide and because of increased rates of physical dis-
orders [1]. Until two decades ago, depression was* Correspondence: cdelascuevas@gmail.com
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article, unless otherwise stated.considered an acute and self-limiting episodic illness.
However, long-term naturalistic studies have revealed
the importance of considering depression as a chronic
lifelong disease with different possible clinical courses in
which symptom severity transverse judgments provide
limited prognostic information. Approximately 70% of
patients recover from major depressive episode during
the first year [2]. However, of those patients who do not
recover within the first year, 10% to 15% remain ill for at
least five years [3]. Of the patients who recover from an
episode of major depression, 22% relapse during the firstentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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a single episode of depression while 75% suffer from a
recurring depression, with one or more recurrences
throughout life [5]. In addition, between one quarter and
two-thirds of patients with major depression suffer co-
morbid dysthymia [6].
Non-adherence to antidepressant medications is a sig-
nificant barrier to the successful treatment of depression
in clinical practice, and this has been linked to poor treat-
ment outcomes such as increased risk of relapse and
recurrence, in addition to increased healthcare costs [7-9].
After four decades of compliance research, the literature
shows that treatment adherence in psychiatric practice is
a multifactorial issue that includes patient-centered fac-
tors, therapy-related factors, healthcare system factors,
clinician-patient alliance and communication factors, so-
cial and economic factors, and disease factors [10-13].
However, despite the relevance of the contribution of that
group of variables in predicting adherence, considerable
accounted variance remains. A recent systematic review
on compliance with prescribed treatment in patients with
depressive disorders has revealed there is no evidence of a
substantial relationship between compliance and socio-
demographic or clinical variables [13]. Under these cir-
cumstances, there is an imperative need to identify major
determinants of non-adherence, particularly those modifi-
able and thus amenable to intervention, which could fa-
cilitate the optimal use of psychotropic medications.
The adherence construct has been reported as a health-
related habit comprised of a set of very different behaviors,
which are not always related to each other [14]. The
health belief model that postulates that health behaviors
are expressions of health beliefs has been proposed to ac-
count for non-adherence to prescribed treatments [15].
Patients' health cognitions should contribute to medica-
tion adherence since they reflect patients' beliefs re-
garding the extent to which they are able to control or
influence their health outcomes based on their personal
experience, the course of their illnesses and the diffe-
rent treatments used.
Having control, or the belief of having control, over
one’s health has been hypothesized to moderate personal
health-promoting behavior [16,17] and has been shown to
be of importance for the wellbeing, quality of life and
functioning of patients with chronic psychiatric disorders
[18-20]. Nevertheless, few studies are available concerning
factors that may influence patients’ sense of control and
that enable finding strategies in mental health interven-
tions to promote these patients’ sense of control and
adherence.
The study of psychological reactance, health locus of
control and the sense of self-efficacy could be of crucial
importance and can help to increase knowledge about
patient’s adherence to treatment. Psychological reactanceis an aversive affective reaction in response to regulations
or impositions that impinge on freedom and autonomy
[21,22], and by means of limiting and threatening free-
dom, recommendations to follow a medication have the
potential to elicit reactance and, as a result, lead patients
to ignore the recommended treatment. Health locus of
control refers to the individual’s beliefs regarding the con-
trol of health [16]. A patient with an internal locus of con-
trol believes that health outcomes are a direct result of
their own behavior, while a patient with an external locus
of control believes that health outcomes are a result of
either chance or other powerful people, such as physi-
cians. Finally, sense of self-efficacy reflects the individual’s
belief in their own skills to plan and perform certain activ-
ities to attain particular aims [23,24] and leads to a greater
sense of confidence and control, translating into a greater
theoretic likelihood of both intending to perform the be-
havior and actually doing so.
None of these psychological characteristics―potential
determinants of adherence to treatment―have been jointly
investigated in depressive disorders. Thus, the aim of this
study was to examine the individual and joint effects of
psychological reactance, health control beliefs, and the
sense of self-efficacy on adherence to a treatment regimen
among psychiatric outpatients with depression. We ex-
pected health locus of control to have a marked effect on
adherence to a treatment regimen, such that internally ori-
ented patients would adhere more than externally oriented
patients. In the same way, we hypothesized that psycho-
logical reactance would also have a marked effect on
adherence to a treatment regimen, such that patients
with low reactance would comply with their physicians'
guidelines and instructions more than patients with
high reactance that would oppose them. Finally, we ex-
pected self-efficacy to have a considerable effect on ad-
herence to a treatment regimen, such that patients with




From January 2013 to May 2013, one hundred and
forty-five consecutive psychiatric outpatients suffering
from depressive disorders seen in two Community Mental
Health Centers on Tenerife Island (Canary Islands, Spain)
were invited to participate in a cross-sectional study; a
total of 119 accepted. Patients were eligible for inclusion
in the study if they were aged 18 and over and were diag-
nosed by their psychiatrists with mood disorders using the
International Classification of Diseases, Tenth Edition
(ICD-10) codes F31 (bipolar affective disorder), F32 (de-
pressive episode), F33 (recurrent depressive disorder), and
F34.1 (Dysthymia). Inclusion into the study required pa-
tients to have received at least one drug prescription. Each
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which they signed an informed consent document ap-
proved by the clinical research ethics committee of Nuestra
Señora de Candelaria Teaching Hospital in Santa Cruz de
Tenerife. Each participant then filled out a brief socio-
demographic survey and the remaining questionnaires.
Measures
Socio-demographic characteristics and clinical variables
Age, sex, educational level (no formal education, primary
studies, secondary studies, and university degree), his-
tory as psychiatric patient (in years), and type of psycho-
active drugs currently taken were assessed. For assessment
purposes the drugs were divided into the common groups
of psychotropic drugs: antidepressants (tricyclics, selective
serotonin reuptake inhibitors [SSRIs] and serotonin and
norepinephrine selective reuptake inhibitors [SNRIs]),
benzodiazepines, antipsychotics (conventional and atyp-
ical) and mood stabilizers. For statistical analysis purposes,
a new variable (number of different drugs) was drawn up
as an indirect measure of treatment complexity. We also
recorded how long patients had been under psychiatric
treatment (in months), the number of different psychia-
trists treating them during that time, and the number of
psychiatric admissions specifying their voluntary or invol-
untary character. Psychiatrists responsible for patient
mental health care were asked about patient diagnosis.
Self-reported adherence
Self-reported adherence to psychiatric medication pre-
scribed was assessed using the Morisky scale [25] in its
Spanish correctly validated version [26], a simple four-item
yes/no self-report instrument commonly used to assess pa-
tient adherence to treatment across a variety of chronic
medical and psychiatric conditions, including affective dis-
orders [27,28]. The Morisky scale includes items querying
whether the patient ever forgot to take medications, was
careless with medications, stopped taking medications at
times when feeling better or discontinued medications
when feeling worse. This scale enables classifying patients
as compliant or non-compliant. Patients are classified as
non-adherent when they answered “yes” to at least one of
the four questions. The scale can also be used as a continu-
ous variable, where maximum adherence is defined as an-
swering “no” to every question. The scale has been shown
to have good reliability (α = .83), and concurrent and pre-
dictive validity in outpatient settings [25,29].
Clinical status
Beck depression inventory (BDI-II)
The Beck Depression Inventory II (BDI-II) is a 21-item
self-report questionnaire that assesses cognitive, beha-
vioral, affective, and somatic symptoms of depression,
developed to correspond to the criteria for DSM-IVdepressive diagnoses [30]. Each item is scored by the
subject on a four-point scale (0–3) according to the way
the participant has been feeling in the previous two
weeks. The 21 items are then summed to give a single
total score for the BDI-II, for which cutoff scores have
previously been established. The cutoffs used differ from
the original: 0–13: minimal depression; 14–19: mild de-
pression; 20–28: moderate depression; and 29–63: severe
depression. Higher total scores indicate more severe
depression-related symptoms. The BDI-II is a reliable and
well-validated measure in screening for depression symp-
toms in adults, with Cronbach's alphas ranging from 0.73
to 0.95. The Spanish validated version by Sanz et al.
(2005) [31] was used.
Psychological features correlates
Three questionnaires were used in the study: the Hong
Psychological Reactance Scale (HPRS), Form C of the
Multidimensional Health Locus of Control Scale (MHLCS)
and the General Self-Efficacy Scale (GSE).
The Hong Psychological Reactance Scale [32] is a 14-
item self-report questionnaire designed to measure the
individual difference in reactance proneness, that is, a
person's trait propensity to experience psychological react-
ance. Psychological Reactance [16] assumes that, when an
individual's freedom is threatened, the individual will be
motivated to restore the perceived loss of freedom. Partici-
pants indicated the extent to which they endorsed each
cognitive or affective statement on a five-point Likert scale
(1 = strongly disagree to 5 = strongly agree). The study
used the validated Spanish version of the scale [33].
Form C of the Multidimensional Health Locus of Con-
trol (MHLC) Scale [34] was used to assess patients’ per-
ception about ‘who’ controls their depression outcomes.
MHLC is an 18-item, general purpose, condition-specific
locus of control self-report scale that could easily be
adapted for use with any medical or health-related con-
dition to assess an individual’s belief on what influences
their health. It is comprised of four subscales: one internal
locus of control subscale: internality and three external
locus of control scales: chance, doctors, and other (power-
ful) people that measure control variables in regard to par-
ticipants’ health. Each item consists of a belief statement
about patient medical condition with which they may
agree or disagree by means of a six-point Likert scale ran-
ging from strongly disagree [1] to strongly agree [6]. The
study used the validated Spanish version of the scale [35].
The General Perceived Self-Efficacy Scale [36] is a 10-
item self-report scale that measures general self-efficacy
as a prospective and operative construct. In contrast to
other scales designed to assess optimism, this scale ex-
plicitly refers to personal agency, i.e., the belief that one's
actions are responsible for successful outcomes. Each
item is scored from 1 (not at all true) to 4 (completely
Table 1 Socio-demographic and clinical characteristics of
the sample studied
Variable Category Number of % of the
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highest score indicating high self-efficacy. The study
used the validated Spanish version of the scale [37].cases sample
Age 30-45 years 26 21.8
Mean Age 56.1 ± 12.0 45-60 years 53 44.5
Rank 30-82 60-75 years 31 26.1
> 75 years 9 7.6
Sex Male 28 23.5
Female 91 76.5














History of psychiatric No 89 74.8Data analysis
Socio-demographic and clinical characteristics were
assessed according to descriptive analyses. An initial cor-
relation analysis was performed to assess the relationship
between psychological processes and their relationship
pattern with traditional contextual variables associated
with adherence to treatment. To contrast adherent and
non-adherent patients in the different variables, one-
factor ANOVA was performed. To predict adherence a
logistic regression analysis was performed to introduce
both nominal and continuous variables together. In
order to test differences in subscale scores, given the dif-
ferent number of items in the MHLC-C and Psycho-
logical Reactance subscales, each subscale score was
computed as the mean of item scores. Also, in order to
contrast the specific role for type of medication used,
chi-squared analyses were performed. Statistical analyses





No. of Psychiatrists 1 29 24.4
Mean 3.4 ± 2.6 2 31 26.1
Rank 1-15 3 19 16.0
Mode 1; Median 3 ≥4 40 33.5
Psychotropic drugs One drug 19 16.0
Mean 2.92 ± 1.45 drugs Two drugs 29 24.4
Rank 1-8 Three drugs 37 31.1












Mood stabilizers 22 18.5
Anticholinergics 2 1.7
Self-reported adherence Adherent 59 49.6
Non-adherent 60 50.4
Abbreviations: ICD International Classification of Diseases, SNRIs Selective
Noradrenaline Reuptake Inhibitors, SSRIs Selective Serotonin Reuptake Inhibitors.Results
We recorded a high response rate of 82.1% resulting in a
sample of 119 psychiatric outpatients suffering from de-
pressive disorders. Table 1 shows the sample distribution
according to socio-demographic and clinical variables in-
cluded in the study. According to the Morisky scale total
scores, slightly more than half the patients (60, 50.4%) were
classified as non-adherent to the treatment prescribed.
An initial analysis (Pearson correlation analysis) was
performed to assess the relationship patterns among the
different psychological processes (self-efficacy, psycho-
logical reactance, and locus of control), and the depres-
sion level (BDI), in order to identify whether there was a
high covariability among them or whether they remain
independents. Correlation coefficients were also obtained
among those processes and the contextual variables usu-
ally associated with treatment compliance (age, educa-
tional level, treatment duration, and number of different
drugs). Finally, using Morisky scale as a continuous vari-
able, level of adherence was correlated with all of those
variables.
Table 2 shows the coefficients obtained. From a total
of 21 correlation coefficients among psychological pro-
cesses, only six attained statistical significance. The most
prominent was the correlation between the two psycho-
logical reactance scales. There was also a considerable posi-
tive correlation between cognitive reactance and Chance
subscale (locus of control). Despite these coefficients, the
general pattern enables identifying the processes as rela-
tively independent by measuring distinctive features.
Table 2 Pearson correlation coefficients (Cramer’s V for sex variable) among the different psychological processes,
contextual variables, and the level of adherence/Morisky scale, in a sample of depressive patients (n = 119)
BDI S-E PR-A PR-C HLC-I HLC-Ch HLC-D HLC-O Adherence
BDI -.61** .28** .42** .01 .35** -.17* -.06 .20*
S-E -.04 -.16 .02 -.14 .15 .26** .04
PR-A .55** -.10 .14 -.05 -.00 .32**
PR-C -.09 .36** -.12 -.04 .25**
HLC-I -.03 .18* .14 .01
HLC-Ch .00 .23* .15
HLC-D .17 -.14
HLC-O .12
Sex(1) .58 .40 .50 .33 .48 .57 .48 .48 .18
Age .05 .07 -.01 -.01 -.10 .02 .10 .13 .16
Educational level -.08 .18* .00 .07 -.04 -.06 .10 -.03 -.06
Treament duration -.07 .10 .05 .01 .02 .10 -.10 .11 .17
No. different drugs .52** -.27** .23* .17* -.06 .14 -.04 .00 .05
Abbreviations: **P < .01; *P < .05; BDI Beck Depression Inventory, PR-A Psychological Reactance, Affective subscale, PR-C Psychological Reactance, Cognitive
subscale, HLC-I Health Locus of Control, Internal subscale, HLC-Ch Health Locus of Control, Chance subscale, HLC-D Health Locus of Control, Doctors subscale,
HLC-O Health Locus of Control, Others subscale, (1) Cramer’s V correlation.
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correlations were registered: negative correlations with
self-efficacy and with an external locus of control (con-
fidence in their doctors). Positive correlations were
obtained for both affective and cognitive psychological
reactance variables, chance external locus of control, and
level of adherence. Also, a positive correlation was found
between the level of depression and higher number of dif-
ferent drugs.
Four statistically significant correlation coefficients
with the contextual variables were found. “Number of
different drugs” was negatively related to self-efficacy and
positively related to psychological reactance (affective and
cognitive). Self-efficacy was also positively related to edu-
cational level. The remaining coefficients did not attainTable 3 Means, standard deviations, and ANOVA between ad
different psychological processes and the level of depression
Variables K-S P Adherent
M SD
HLC –Internal .72 .673 3.56 1.11
HLC –Chance 1.08 .192 3.17 1.12
HLC –Doctors 1.65 .009 5.05 0.98
HLC –Others .84 .485 3.60 1.28
PR –Affective .64 .801 3.04 0.88
PR –Cognitive .91 .379 1.87 0.77
Self-Efficacy .71 .697 25.24 6.81
BDI 1.15 .144 18.23 11.09
Abbreviations: HLC Health Locus of Control, PR Psychological Reactance, BDI Beck De
P probability, SD Standard Deviation.statistical significance (some of them with correlations
close to zero).
Only psychological reactance subscales (affective and
cognitive) attained statistical significance with level of
adherence, and both in the same direction: as reactance
increases there is a lower level of adherence.
A second group of analyses was performed to determine
whether the levels in those psychological processes dif-
fered between compliant and non-compliant patients (ac-
cording to categoric Morisky scale classification). Table 3
summarizes the ANOVA obtained (each variable was ana-
lyzed independently), including means, standard devia-
tions of locus of control, reactance, and self-efficacy, and a
test of normal distribution. As can be observed, the exter-
nal locus of control variable ‘Doctors’ (the patients’ beliefherent and non-adherent depressive outpatients on
Non-adherent F P Partial
η2M SD
3.40 1.22 .55 .459 .005
3.33 1.00 .69 .409 .006
4.68 0.96 4.28 .041 .035
3.69 1.25 .15 .699 .001
3.50 0.72 9.57 .002 .076
2.24 0.70 7.48 .007 .060
25.67 6.32 .13 .722 .001
19.15 10.39 .13 .724 .002
pression Inventory, K-S Kolmogorov-Smirnov’s z, M median,
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depressive disorder), is not normally distributed.
On examination of the ANOVA results, three statisti-
cally significant differences were recorded in the cognitive
factors studied; one variable was related to health locus of
control and two variables refer to the psychological reac-
tance construct. Adherent patients scored higher on the
MHLC Doctors subscale, although this result must be
taken with caution because of its non-normal distribution.
No other health locus of control variables attained statis-
tical significance. As for psychological reactance, both
affective and cognitive subscales attained statistically sig-
nificant differences between adherent and non-adherent
patients: non-adherence patients scored higher for both
measures, indicating more of a reactance stance when pa-
tients do not follow medical prescriptions.
Taking into account the pattern of correlation coeffi-
cients and the differences observed in the last ANOVAs,
a logistic regression analysis was performed to ascertain
the relative role of these cognitive factors and health cog-
nitions in predicting adherence to prescribed treatment. A
step-by-step method was used to select only those vari-
ables that play a significant role predicting adherence.
Also, to know the stability of the model, a new logistic re-
gression was performed with a random sample (50%).
Subsequently, the model obtained was tested with the
rest of the sample. Table 4 summarizes the coefficients
obtained.
According to Wald coefficients, only three variables
attained statistical significance. Age was the best predictor
of adherence to prescribed treatment; older patients were
less likely to be adherent. The following variables in the
regression analysis refer to psychological processes: a
negative association with an external locus of control
(there is more compliance when patients rely on theirTable 4 Logistic regression predicting compliant and
non-compliant depressive patients, according to psycho-
logical processes and contextual variables
A)Total sample (n = 119)
B Wald P OR 95% CI
Age .07 12.95 .000 1.07 1.03 1.12
HLC-Doctors -.20 6.42 .011 .82 .71 .96
PR-Affective .11 9.36 .002 1.12 1.04 1.20
Constant −3.91 5.40 .020 .020
B) Random sample (n = 60)
B P OR
Age 0.07 0.02 1.07
HLC-Doctors −0.30 0.02 0.74
PR-Affective 0.13 0.02 1.14
Constant −2.85 0.26 0.06
Abbreviations: B beta coefficients, CI confidence interval, HLC Health Locus of
Control, OR Odds ratio, P probability, PR Psychological Reactance.physicians), and a positive relationship with affective
reactance, where more reactant patients were less compli-
ant. Variables usually associated with adherence such as
treatment complexity (number of different drugs), and
treatment duration did not attain statistical significance.
This general model attained statistical significance (X2
(3) = 29.03; p = .000), with a 73% of patients correctly
classified (cut-off point .50).
The logistic regression with a random sample (n = 60)
attained a similar pattern, with the same three variables
into the equation. In this case the percentage of cases cor-
rectly classified was 71%. Finally, the projection of this
model over the rest of the sample raised a 66% of cases
correctly classified.
To ascertain whether there was a specific role for type
of medication, Chi-squared analyses were performed for
adherence and no-adherence patients and patients who
were or were not taking antidepressants, antipsychotics,
anxiolytics, or mood stabilizers. No statistically significant
differences were obtained (antidepressants: X2[1] = .98;
antipsychotics: X2[1] = 1.67; benzodiazepines: X2[1] = .08;
mood stabilizers: X2[1] = .01).
Discussion
The results of this study show statistically significant as-
sociations between age, psychological reactance and doc-
tor-attributed health locus of control and adherence to
drug treatment in psychiatric outpatients with depression.
Among the socio-demographic factors, age was the
variable most consistently related to adherence; older
patients were less likely to be adherent. This finding is
not in line with that of some previous studies, which
found a statistically significant association between older
age and a lower probability of (or a longer time to) dis-
continuation [13]. Although poor adherence to prescribed
regimens could affect all age groups the prevalence of cog-
nitive and functional impairments in elderly patients in-
creases their risk of poor adherence in the same way as
the presence of multiple co-morbidities, the polypharmacy
associated and the subsequent complex medical regimens
[38-40]. Moreover, age-related pharmacokinetic and phar-
macodynamic abnormalities make this population even
more vulnerable to non-adherence by increasing the side
effects likely to be experienced from therapy [41,42].
Among the beliefs of having control over one’s health,
contrary to some of our hypotheses, not all variables stud-
ied influenced the health behavior of adherence since only
psychological reactance led to recording a statistically sig-
nificant association with self-reported adherence. As ex-
pected, there was more reactance (especially affective
reactance) in less adherent patients. The hypothesis that
highly psychological reactant patients would be more
likely to be noncompliant than patients showing a low
level of psychological reactance was confirmed by our
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structions and advice, while people with high reactance
commonly resist any guidance or assistance. People with
high reactance usually have a change style focused on
their own resources, personal decisions and initiatives (in-
ternal attribution of change), while people with low react-
ance often seek external help and support to achieve their
goals (external attribution change).
The MHLC scales results obtained appear to confirm
the idea that depressive patients have appropriate beliefs
concerning the management of their condition, and de-
fine themselves as informed and aware of the specific
‘commitment rules’ related to depression and, therefore,
skilled at exercising due control over it. The higher mean
score recorded by depressive patients on the Doctor sub-
scale suggests that depressive patients believe their clini-
cians play a crucial role in improving their state of health.
As for the Other People scale, depressive patients appear
to attribute major importance to ‘meaningful others’ in
the management of their illness; they believe that interper-
sonal relationships are fundamentally necessary to manage
their condition and, in addition, they have no difficulties
placing trust in others. The patients’ high scores on the
Internality subscale are indicative, as shown in several pre-
vious studies [43], that depressive patients are generally
skilled at controlling their pathology and can modify their
behavior patterns, in order to improve their state of
health. The lower scores on the Chance scale indicate that
depressive patients tend to attribute less significance to
‘fate and destiny’ in determining the course of their illness.
However, regarding health locus of control influence
on adherence to depression treatment, although intern-
ally oriented patients’ self-reported higher adherence to
prescribed treatment than externally oriented patients,
the differences were not statistically significant. Only the
doctors’ subscale was identified as a crucial determinant
of adherence with prescribed treatment, with adherent
patients scoring significantly higher in believing that psy-
chiatrists were responsible for an improvement in their
depression. This general absence of relationship of locus
of control with adherence could be mediated by the
treatment decision-making. Locus of control is a dimen-
sion related to the causality of the phenomena: perhaps
if patients feel they are a significant part of the treatment
outcome, locus of control dimensions would play a rele-
vant role in adherence.
In the case of the self-efficacy process, the absence of
differences between adherent and non-adherent patients
can be accounted for because it is possible this feature is
more related to treatment outcome than treatment
process. It is expected that if a patient trusts themself to
solve their health problem, they will be more compliant
with treatment. However, once again, as we argued for
locus of control dimensions, this expectation could bemodulated by the treatment decision-making process.
Further studies need to be carried out.
Our study has some limitations related to the method-
ology applied, which need to be recognized. First, al-
though a high rate of participation was recorded in our
study, our results could be affected by a selection bias,
in that it could be differences in psychological features
between those who agree and disagree to participate in
our study. Second, our study included a convenient sam-
ple of consecutive psychiatric outpatients with depres-
sive disorders who attend community mental health
centers and this sample may not be representative of the
entire population of depressive patients. Third, all ques-
tionnaires applied were self-reports, which could be re-
lated to a potential risk of misstatement or could involve
response biases. Finally, another limitation of the study
is the fact that only one method of estimating adherence
was used. At present, several direct and indirect methods
for measuring adherence are available. Each method has
advantages and disadvantages, and no method is consid-
ered the gold standard. Patient questionnaires, i.e. patient
self-reports, are the most useful in the clinical setting
since they are simple, inexpensive and effectively measure
adherence [44-46]. Future studies of the effect of psycho-
logical reactance and health locus of control would utilize
multiple assessments of adherence (e.g. pharmacy records
and self-report). As a result of the limitations reported,
some caution is recommended in order to generalize our
findings beyond the group studied.
The role shown by our study for psychological react-
ance in adherence to prescribed treatment for depressed
patients would have important implications for clinical
practice. Depressed patients with high psychological react-
ance may perceive a large amount of clinical advice to be
a threat to their freedom, and may therefore attempt to
reassert this freedom through oppositional or non-
compliant behavior [47]. If depressed, reactance prone
patients perceive treatment provision to be a threat to
their freedom of choice, mental health professionals should
be alerted in such a way so as to avoid inducing reactance,
and thus non-adherence, to prescribed treatment. Any per-
suasive message may arouse a motivation to reject the
advocacy [48]. Reactant people have a tendency to act
without considering potential consequences [49].
In light of the results evidenced in our study it appears
important and useful that mental health professionals
learn about communication techniques and counseling
skills that allow them to avoid the so-called communica-
tion barriers: doctors' interventions which can cause
non-adherence and hostile attitudes in the patient to-
wards changes [50]. Adequate communication and part-
nership are not only desirable aims, but they are also
possible in the mental health care of depressive patients
that implements the basic rights of a group of patients
De las Cuevas et al. BMC Psychiatry 2014, 14:324 Page 8 of 9
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powerment. Adherence to treatment will benefit from
enhancing patients' view that they are responsible for
their treatment decisions and when the patients’ view-
point are taken into account. Nevertheless, this paper is
exploratory in nature, and should be read with caution;
generalizations should be avoided in the absence of dir-
ect empirical evidence of a link between reactance and
health behavior. At this time, It would be prudent to
hold off making clinical recommendations or trying to
generalize the findings to psychiatric patients in general.
Conclusions
Psychological reactance is an important correlate of ad-
herence to treatment in patients with depressive disorders
and this needs to be considered when giving clinical advice
in order to avoid inducing reactance and thus non-
adherence to prescribed treatments. Mental health profes-
sionals need to learn about communication techniques and
counseling skills that enable them to deal with the psycho-
logical reactance of their patients.
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